Jane Street Group LLC Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Jane Street Group LLC lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 41.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 30,793 shares of the company's stock after selling 22,212 shares during the period. Jane Street Group LLC owned approximately 0.07% of Enliven Therapeutics worth $786,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its holdings in shares of Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after acquiring an additional 601,611 shares during the period. Janus Henderson Group PLC grew its stake in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock valued at $26,611,000 after purchasing an additional 313,019 shares during the period. State Street Corp increased its position in shares of Enliven Therapeutics by 2.9% during the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock valued at $19,051,000 after purchasing an additional 21,018 shares during the last quarter. First Turn Management LLC lifted its stake in shares of Enliven Therapeutics by 29.5% in the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after purchasing an additional 121,849 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics by 10.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock worth $6,520,000 after purchasing an additional 24,043 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $28.15, for a total value of $470,386.50. Following the sale, the chief executive officer now directly owns 1,003,816 shares in the company, valued at approximately $28,257,420.40. The trade was a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 847 shares of the business's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $25,410.00. Following the completion of the sale, the insider now owns 1,015,188 shares in the company, valued at approximately $30,455,640. The trade was a 0.08 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 92,853 shares of company stock worth $2,577,630. 29.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. BTIG Research initiated coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a "buy" rating and a $42.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, Robert W. Baird lifted their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $38.25.

Enliven Therapeutics Stock Performance

Shares of ELVN traded up $0.52 during mid-day trading on Friday, reaching $24.42. The stock had a trading volume of 249,260 shares, compared to its average volume of 209,980. The business has a fifty day moving average of $25.01 and a 200 day moving average of $24.30. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -12.85 and a beta of 1.02. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.